$61.13
-5.1%GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Chief Commercial Officer
Chief Executive Officer & Director
Compensation
$1,539,701
Chief Financial Officer
Compensation
$817,800
Chief Scientific Officer & President International
General Counsel
President
Compensation
$1,040,820
President of International Business & BioPharma
Senior Vice President of Clinical Development
Senior Vice President of Global Development & Operations
Senior Vice President of Government Affairs
Senior Vice President of Human Resources & Head of People Team
Senior Vice President of Research, Development & Operations
During the last 12 months, insiders have sold $104.57M worth of GRAL shares, with no buying activity reported.
0
0.00
233.4K
11.64M
-11.6M
-$11.64M
0
0.00
1.4K
75.03K
-75K
-$75K
0
0.00
1.1M
90.06M
-90.1M
-$90.06M
0
0.00
60.3K
2.79M
-2.8M
-$2.79M
No buying activity
Illumina, Inc.
10 Percent Owner
$79.85M
Ofman Joshua J.
Director, Officer: President
$12.35M
Ragusa Robert P
Director, Officer: Chief Executive Officer
$8.06M
Freidin Aaron
Officer: Chief Financial Officer
$2.91M
Ding Chun R
10 Percent Owner
$1.40M
Strong bearish signal with $104.57M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
GRAL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | May 29, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | May 29, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.